Prognostic factors and effectiveness of the first-line therapy for chronic lymphocytic leukemia: results of 10-year follow-up
О. B. Kalashnikova,
M. O. Ivanova,
N. P. Volkov,
E. V. Kondakova,
E. A. Izmailova,
I. M. Barhatov,
T. L. Gindina,
E. V. Babenko,
A. D. Kulagin,
N. B. Mikhailova,
I. S. Moiseev https://doi.org/10.24884/1607-4181-2020-27-3-80-96
Abstract
Introduction.The biological heterogeneity of chronic lymphocytic leukemia (CLL) is reflected in the rate of progression, the need for therapy, and the response to treatment. Analysis of prognostic factors contributes to improving the quality of treatment and rational distribution of healthcare resources.
Materials and methods. Among 890 patients with documented stage of CLL, 405 (45.5 %) received treatment. As the first-line of treatment, 173 patients received intensive regimens (FCR or BR), 6 – new agents, and 226 – all other regimens. The initial stage of the disease, mutation status of IGHV, del17p with or without complex karyotype were analyzed as prognostic markers.
Results. Immunochemotherapeutic regimens were shown to be highly effective in case planned amount of treatment was completed. The combination of such prognostic parameters as the initial stage of the disease, the mutation status of IGHV, and the presence of del17p and/or complex karyotype allows us to clearly identify a group of patients with an unfavorable prognosis, for which it is advisable to use either intensive programs or new agents in the first-line therapy.
About the Authors
О. B. Kalashnikova
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Kalashnikova Оlga B., Hematologist of the Hematological Department of the Polyclinic with CDC
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest.
The authors confirm that they respect the rights of the people participated in the study, including obtaining informed consent when it is necessary, and the rules of treatment of animals when they are used in the study. Author Guidelines contains the detailed information.
M. O. Ivanova
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Ivanova Maria O., Cand. of Sci. (Med.), Head of the Hematological Department
of the Polyclinic with CDC
Saint Petersburg
Competing Interests:
Authors declare no conflict of interest.
The authors confirm that they respect the rights of the people participated in the study, including obtaining informed consent when it is necessary, and the rules of treatment of animals when they are used in the study. Author Guidelines contains the detailed information.
N. P. Volkov
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Volkov Nikita P., Hematologist of the Oncology Department № 2 (Сhemotherapy and BMT), Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation
Saint Petersburg
Competing Interests:
Authors declare no conflict of interest.
The authors confirm that they respect the rights of the people participated in the study, including obtaining informed consent when it is necessary, and the rules of treatment of animals when they are used in the study. Author Guidelines contains the detailed information.
E. V. Kondakova
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Kondakova Elena V., Cand. of Sci. (Med.), Hematologist of the Oncology Department № 2 (Сhemotherapy and BMT), Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation
Saint Petersburg
Competing Interests:
Authors declare no conflict of interest.
The authors confirm that they respect the rights of the people participated in the study, including obtaining informed consent when it is necessary, and the rules of treatment of animals when they are used in the study. Author Guidelines contains the detailed information.
E. A. Izmailova
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Izmailova Ekaterina A., Geneticist of the Laboratory of Transplantology and Molecular Hematology, Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation
Saint Petersburg
Competing Interests:
Authors declare no conflict of interest.
The authors confirm that they respect the rights of the people participated in the study, including obtaining informed consent when it is necessary, and the rules of treatment of animals when they are used in the study. Author Guidelines contains the detailed information.
I. M. Barhatov
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Barhatov Ildar M., Cand. of Sci. (Med.), Leading Research Fellow of the Department of Clinical Oncology, Head of the Laboratory of Transplantology and Molecular Hematology, Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation
Saint Petersburg
Competing Interests:
Authors declare no conflict of interest.
The authors confirm that they respect the rights of the people participated in the study, including obtaining informed consent when it is necessary, and the rules of treatment of animals when they are used in the study. Author Guidelines contains the detailed information.
T. L. Gindina
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Gindina Tatiana L., Dr. of Sci. (Med.), Head of the Laboratory of Cytogenetics and Diagnostics of Genetic Diseases, Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation
Saint Petersburg
Competing Interests:
Authors declare no conflict of interest.
The authors confirm that they respect the rights of the people participated in the study, including obtaining informed consent when it is necessary, and the rules of treatment of animals when they are used in the study. Author Guidelines contains the detailed information.
E. V. Babenko
Pavlov University
Competing Interests:
Babenko Elena V., Head of the Department of Cryopreservation with the Laboratory of Quality Control of Hematopoietic Cells, Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation
Saint Petersburg
Competing Interests:
Authors declare no conflict of interest.
The authors confirm that they respect the rights of the people participated in the study, including obtaining informed consent when it is necessary, and the rules of treatment of animals when they are used in the study. Author Guidelines contains the detailed information.
A. D. Kulagin
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Kulagin Alexander D., Dr. of Sci. (Med.), Head of the Department of Hematology,
Transfusiology, Transplantology the Faculty of Postgraduate Education, Acting Director of Raisa Gorbacheva Memorial Research Institute of Children Oncology
Saint Petersburg
Competing Interests:
Авторы заявили об отсутствии потенциального конфликта интересов.
Авторы подтверждают, что соблюдены права людей, принимавших участие в исследовании, включая получение информированного согласия в тех случаях, когда оно необходимо, и правила обращения с животными в случаях их использования в работе. Подробная информация содержится в Правилах для авторов.
N. B. Mikhailova
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Mikhailova Natalya B., Cand. of Sci. (Med.), Associate Professor of the Department of Hematology, Transfusiology, Transplantology of the Faculty of Postgraduate Education, Head of the Department of Clinical Oncology, Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation
Saint Petersburg
Competing Interests:
Authors declare no conflict of interest.
The authors confirm that they respect the rights of the people participated in the study, including obtaining informed consent when it is necessary, and the rules of treatment of animals when they are used in the study. Author Guidelines contains the detailed information.
I. S. Moiseev
Pavlov University
Competing Interests:
Moiseev Ivan S., Dr. of Sci. (Med.), Associate Professor of the Department of Hematology, Transfusiology, Transplantology of the Faculty of Postgraduate Education, Deputy Director of Raisa Gorbacheva Memorial Research Institute of \ Children Oncology
Saint Petersburg
Competing Interests:
Authors declare no conflict of interest.
The authors confirm that they respect the rights of the people participated in the study, including obtaining informed consent when it is necessary, and the rules of treatment of animals when they are used in the study. Author Guidelines contains the detailed information.
References
1. Rozman C., Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333(16):1052–1057. Doi: 10.1056/NEJM199510193331606.
2. Catovsky D., Muller-Hermelink H. K., Montserrat E., Harris N. L. B-cell prolymphocytic leukaemia. In: Harris N. L., Stein H., Vardiman J. W., eds. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001:131–132.
3. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M. J. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66. Doi: 10.3322/canjclin.57.1.43.
4. Sant M., Allemani C., Tereanu C. et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–3734. Doi: 10.1182/blood-2010-05-282632.
5. Kaprin A. D., Starinsky V. V., Petrova G. V., eds. Malignant neoplasms in Russia in 2018 (morbidity and mortality). Moscow, P. A. Herzen Moscow state medical research Institute branch of the Federal state budgetary institution «NMIC of radiology» of the Ministry of health of Russia, 2019. (In Russ.).
6. Rai K. R., Sawitsky A., Cronkite E. P., Chanana A. D., Levy R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood. 2016;128(17):2109. Doi: 10.1182/blood-2016-08-737650.
7. Binet J. L., Auquier A., Dighiero G. et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198–206. Doi: 10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v.
8. Ballman K. V. Biomarker: Predictive or Prognostic? J Clin Oncol. 2015;33(33):3968–3971. Doi: 10.1200/JCO.2015.63.3651.
9. Döhner H., Stilgenbauer S., Benner A. et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916. Doi: 10.1056/NEJM200012283432602.
10. Bieging K. T., Attardi L. D. Deconstructing p53 transcriptional networks in tumor suppression. Trends Cell Biol. 2012;22(2):97–106. Doi: 10.1016/j.tcb.2011.10.006.
11. Landau D. A., Tausch E., Taylor-Weiner A. N. et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525–530. Doi: 10.1038/nature15395.
12. Hallek M., Cheson B. D., Catovsky D. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. Doi: 10.1182/blood-2017-09-806398.
13. International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779–790. Doi: 10.1016/S1470-2045(16)30029-8.
14. Zenz T., Mertens D., Küppers R., Döhner H., Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10(1):37–50. Doi: 10.1038/nrc2764.
15. Hamblin T. J., Davis Z., Gardiner A., Oscier D. G., Stevenson F. K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–1854.
16. Damle R. N., Wasil T., Fais F. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840–1847.
17. Thompson P. A., Tam C. S., O’Brien S. M. et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127(3):303–309. Doi: 10.1182/blood-2015-09-667675.
18. Baliakas P., Jeromin S., Iskas M. et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133(11):1205–1216. Doi: 10.1182/blood-2018-09-873083.
19. Rai K. R., Peterson B. L., Appelbaum F. R. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750–1757. Doi: 10.1056/NEJM200012143432402.
20. Knauf W. U., Lissitchkov T., Aldaoud A. et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol. 2012;159(1):67–77. Doi: 10.1111/bjh.12000.
21. Hallek M., Fischer K., Fingerle-Rowson G. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–1174. Doi: 10.1016/S0140-6736(10)61381-5.
22. Tsiara S., Christou L., Konstantinidou P., Panteli A., Briasoulis E., Bourantas K. L. Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia. Am J Hematol. 1997;54(4):342.
23. Gonzalez H., Leblond V., Azar N. et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol Cell Ther. 1998;40(3):113–118.
24. Martell R. E., Peterson B. L., Cohen H. J. et al. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study. Cancer Chemother Pharmacol. 2002;50(1):37–45. Doi: 10.1007/s00280-002-0443-5.
25. Leporrier M., Reman O., Troussard X. Pure red-cell aplasia with fludarabine for chronic lymphocytic leukaemia. Lancet. 1993;342(8870):555.
26. Cuneo A., Marchetti M., Barosi G. et al. Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group. Leuk Res. 2014;38(11):1269–1277. Doi: 10.1016/j.leukres.2014.06.017.
27. Eichhorst B., Fink A. M., Bahlo J. et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–942. Doi: 10.1016/S1470-2045(16)30051-1.
28. Nikitin E., Kisilichina D., Zakharov O. et al. Randomised Comparison Of FCRLite And ClbR (Chlorambucil Plus Rituximab) Regimens In Elderly Patients With Chronic Lymphocytic Leukemia. Hematologica. 2013;98 (Suppl 1):473.
29. Foon K. A., Mehta D., Lentzsch S. et al. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood. 2012;119(13):3184–3185. Doi: 10.1182/blood-2012-01-408047.
30. Shvidel L., Shtalrid M., Bairey O. et al. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2003;44(11):1947– 1950. Doi: 10.1080/1042819031000110991.
31. Goede V., Fischer K., Busch R. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–1110. Doi: 10.1056/NEJMoa1313984.
32. Byrd J. C., Furman R. R., Coutre S. E. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42. Doi: 10.1056/NEJMoa1215637.
33. Stilgenbauer S., Eichhorst B., Schetelig J. et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018;36(19):1973–1980. Doi: 10.1200/JCO.2017.76.6840.
34. Byrd J. C., Furman R. R., Coutre S. E. et al. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clin Cancer Res. 2020;26(15):3918– 3927. Doi: 10.1158/1078-0432.CCR-19-2856.
35. Farooqui M. Z., Valdez J., Martyr S. et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169–176. Doi: 10.1016/S1470-2045(14)71182-9.
36. Stilgenbauer S., Eichhorst B., Schetelig J. et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018;36(19):1973–1980. Doi: 10.1200/JCO.2017.76.6840.
37. Stadnik Ye. A., Nikitin Ye. A., Biderman B. V., Salogub G. N., Lorie Yu. Yu., Tsyba N. N., Alexeeva Yu. A., Doronin V. A., Mashuk V. N., Vabishevich R. I., Melikyan A. L., Kolosheinova T. I., Kolosova L. Yu., Sudarikov A. B., Kovaleva L. G., Zaritsky A. Yu. Comparison of efficacy and toxicity of FC and FCR regimens in the treatment of primary B-cell chronic lymphocytic leukemia: a retrospective study. Oncohematology. 2008;1(2):39–46. (In Russ.).
38. Zukhovitskaya Е., Fiyas А., Chaykovskaya O. Clinical efficiency of combination of bendamustine + rituximab in first line treatment of chronic lymphocytic leukemia and patients with recurrent disease. Journal of the Grodno State Medical University. 2015;1(49):114–116. (In Russ.).
39. Nikitin E. A., Dmitrieva E. A., Panteleev M. A., Emelina E. I., Ivanova V. L., Kochkareva Yu. B., Arshanskaya E. G., Lazarev I. E., Markova E. E., Mukha L. A., Novitskaya N. G., Pankrashkina M. M., Glazunova V. V., Shubina A. V., Chernysh S. A., Khuazheva N. K., Naumova E. V., Lugovskaya S. A., Pochtar` M. E., Obukhova T. N., Vinogradova O. Yu., Gendlin G. E., Ptushkin V. V. Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia. Clinical oncohematology. 2017;10(3):271–281. (In Russ.).
40. Stadnik Ye. A., Timofeeva N. S., Strugov V. V., Zaritskii A. Yu. Ibrutinib in the treatment of relapsed chronic lymphocytic leukemia. Clinical oncohematology. 2018; 11(1):42–49. (In Russ.).
41. Poddubnaya I. V., еds. Selected issues of Oncohematology. Chronic lymphocytic leukemia. Moscow, Buki Vedi, 2017;(2):85. (In Russ.).
42. Hallek M., Cheson B. D., Catovsky D. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456. Doi: 10.1182/blood-2007-06-093906.
43. Cheson B., Fisher R., Barrington S. et al. Recommendations for Initial Evaluation, Staging and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma – the Lugano Classification. J Clin Oncol. 2014;32:3059–3068.
44. Rosenquist R., Ghia P., Hadzidimitriou A. et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. Leukemia. 2017;31(7):1477–1481. Doi: 10.1038/leu.2017.125.
45. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J Am Statis Assn. 1958;53(282):457-481.
46. Rai K. R., Han T. Prognostic factors and clinical staging in chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 1990;4(2):447–456.
47. Ahn I. E., Farber C. M., Davids M. S. et al. Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. Blood Adv. 2017;1(25):2433–2443. Doi: 10.1182/bloodadvances.2017011262.
48. World Health Organization. Available at: https://www.who.int/publications/data/gho/data/themes/topics/in-dicator-groups/indicator-group-details/GHO/life-expectancy-and-healthy-life-expectancy, as of 08/2020 (accessed: 12.08.2020).
49. Weide R., Feiten S., Chakupurakal G. et al. Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017. Leuk Lymphoma. 2020;61(3):557–566. Doi: 10.1080/10428194.2019.1680840.
Review
For citations:
Kalashnikova О.B., Ivanova M.O., Volkov N.P., Kondakova E.V., Izmailova E.A., Barhatov I.M., Gindina T.L., Babenko E.V., Kulagin A.D., Mikhailova N.B., Moiseev I.S. Prognostic factors and effectiveness of the first-line therapy for chronic lymphocytic leukemia: results of 10-year follow-up. The Scientific Notes of the Pavlov University. 2020;27(3):80-96. (In Russ.) https://doi.org/10.24884/1607-4181-2020-27-3-80-96
Views:
876
Email this article 